News and Trends 15 Jun 2018 London Pharma Company Rakes in Positive Results for Two HIV Phase III Trials ViiV Healthcare obtained positive Phase III results for its two-drug HIV treatment regimen, which could reduce toxicity as compared to the standard three-drug HIV treatments normally given to patients. ViiV Healthcare, a British company, has positive results from two Phase III trials that compared the safety and efficacy of its two-drug HIV treatment regimen to […] June 15, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jun 2018 Device Helps Protect Cereals by Diagnosing Herbicide Resistance in Weeds Mologic and Newcastle University have launched a diagnostic device that provides rapid information on herbicide resistance for a common weed, which could help cut major losses for the British agricultural industry. The partnership between academia and industry has developed a device that can diagnose herbicide resistance in the blackgrass weed, which could help farmers protect […] June 14, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2018 Microbiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD UK biotech Microbiotica has entered into a multi-year collaboration with Genentech, one of the world’s first biotechs, to develop microbiome-based treatments for inflammatory bowel disease. Microbiotica, based in Cambridge, UK has entered into a collaboration with Genentech that could be worth up to €452M ($534M), a formidable amount in the microbiome space, with an undisclosed […] June 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2018 British Researchers Regenerate Tooth Enamel With Biopolymers Researchers at Queen Mary University London have found a way to grow mineralized materials that can be used to regenerate hard tissue like dental enamel. British researchers have created a material that can be used as an artificial dental enamel to prevent and treat tooth decay or tooth sensitivity. To create the enamel, the scientists […] June 5, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jun 2018 British Company Gets a $100M Boost to Develop a Surgical Robotic Arm CMR Surgical has raised an impressive Series B round to develop a robotic arm to help during surgery that mirrors the movement of a human arm. CMR Surgical, based in Cambridge, UK, has raised $100M (€85M) in Series B funding to bring its surgical robot technology closer to a market launch in Europe and the US. […] June 4, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 15 May 2018 An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials CellCentric has raised a private round to fund the development of a first-in-class drug with potential to tackle treatment-resistant prostate cancer. Cambridge-based CellCentric has raised $26M from Morningside Venture Investments. The company plans to use the cash to fund the development of an epigenetic cancer drug up to Phase 2b trials. The drug in question, called CCS1477, […] May 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 11 May 2018 This Oxford Biotech is Using DNA to Find New Peptide Drugs Today, we’re in Oxford, UK, visiting Orbit Discovery. The biotech develops peptide drugs for chronic diseases using DNA to tag potential therapeutic proteins. Mission: Orbit Discovery develops peptide drugs for a range of conditions including metabolic, autoimmune and cardiovascular diseases using beads to connect peptides to the DNA that encodes them and see how well the peptides […] May 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2018 FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease Orchard Therapeutics has received a fourth Rare Pediatric Disease Designation from the FDA for its gene therapy candidate for metachromatic leukodystrophy. Orchard Therapeutics, based in London, has received a Rare Pediatric Disease Designation form the FDA for its gene therapy OTL-200. The treatment is for patients with metachromatic leukodystrophy (MLD), a fatal genetic disease that causes […] May 3, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 12 Apr 2018 Graphene Skin Patch Measures Blood Sugar Without a Needle Researchers in the UK have developed a skin patch that measures blood sugar levels without the prick of a needle by pulling fluid out from between hair follicles. The technology could be used for both type 1 and type 2 diabetes patients. Diabetes is a major global health problem, with the World Health Organization stating 422 […] April 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2018 DNA Sequencing Unicorn Oxford Nanopore Raises £100M Round at £1.5Bn Valuation Undeterred by competitors, Oxford Nanopore, one of the few unicorns in the biotech space, has secured £100M (€113M) to continue growing its unique next-generation sequencing platform. Oxford Nanopore is one of the best-funded biotechs in Europe, having raised £507.3M (€578M) in total, and famous for its “DNA-reading gadget the size of a Mars bar that sells for $1,000.” The company plans to […] March 20, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 20 Mar 2018 Oxford Firm Develops Better Test for ALS Diagnosis Oxford BioDynamics has presented data from a new diagnostic test that could help not just diagnose ALS but also help patients get a personalized treatment. Amyotrophic lateral sclerosis (ALS) is a motor neuron disease whose diagnosis comes with the hard news that most patients die merely within 3 to 5 years of diagnosis. One of […] March 20, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Mar 2018 New Antibiotic for MRSA Infections is Ready for US Clinical Trials Update (15/03/2018): The FDA has granted Fast Track Designation to XF-73, an antibody being developed by Destiny Pharma against post-surgical MRSA infections. Originally published on 26/02/2018 Destiny Pharma’s antibiotic for post-surgical infections will begin its clinical development after the FDA accepted its Investigational New Drug application. Destiny Pharma wants to combat the growing antibiotic resistance […] March 15, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email